Background
Type 1 diabetes (T1D) is a common endocrine disorder found in adolescents worldwide, caused by an autoimmune destruction of pancreatic beta-cells [
1]. For a long time, T1D was associated with a lean phenotype [
1] but in the last decades, obesity has been present among these patients even at diagnosis [
2]; however, it can also appear after the initiation of insulin treatment that can contribute to weight gain and clinical characteristics of insulin resistance [
3]
Patients with T1D that present obesity and other clinical features of insulin resistance at diagnosis or those who gain weight during treatment are termed as having double-diabetes [
4‐
6]. In general patients with overweight/obesity show other components of insulin resistance or metabolic syndrome (MS) that are risk factors for the presence of diabetes-related chronic complications (DRCC) [
7‐
9]. A recent meta-analysis has found that approximately one quarter (23.7%) of patients with T1D were affected by MS [
10]. The presence of MS or insulin resistance are considered as risk factors for the presence of poor glycemic control, CKD and cardiovascular diseases (CVD) [
7] and retinopathy [
9]. Recently, MS was also associated with the presence non-alcoholic fatty liver disease (NAFDL) in patients with T1D as has recently been demonstrated in a study carried out in a tertiary care center in our country [
8]. In this study, patients with altered hepatic images on ultrasound or transient elastography had higher body mass index (BMI) and presence of MS [
8].
Some studies have found an association between weight gain and intensive insulin therapy even in those using insulin pumps [
6,
11,
12]. Subgroup analyses of the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) have found that patients who gained weight during the trial presented features associated with increased cardiovascular risk and those in the highest quartile for weight gain exhibited higher blood pressure and a more atherogenic lipid profile [
6]. In the same study, those patients in the intensive insulin therapy gained twice as much weight compared to those under conventional care [
11]. Greater weight gain was associated with poorer glycemic control at baseline, greater decrease in HbA1c levels, presence of severe hypoglycemic episodes but had no relationship with caloric intake and with physical activity intensity. It is supposed that a decrease in glycosuria and consequent better calorie utilization or even other unknown mechanisms are involved in this process [
11,
13].
This study aims primarily to investigate the prevalence of overweight and/or obesity and its associated cardiovascular risk factors in Brazilian adolescents with T1D and secondly its association with DRCC.
Discussion
Our study has shown that almost one quarter of our adolescents with T1D, presented overweight/obesity. Having overweight/obesity was associated with some traditional risk factors for DRCC and CVD such as diabetes duration, hypertension, LDL-cholesterol and MS. The above-mentioned data pointed out that these patients aggregated factors associated with micro and macrovascular DRCC which could translate into poor clinical prognosis in the future [
34‐
36]. Although no association was found with glycemic control (current and in the previous year) it is important to emphasize that less than 20% of the patients in both groups presented an adequate glycemic control. No association was found between overweight/obesity with diabetic CKD, retinopathy and laboratorial markers of NAFLD.
The prevalence of overweight/obesity in patients with T1D ranged from 12 to 38.5% in studies conducted in different countries [
2,
14,
37‐
40]. Our study showed a prevalence of overweight/obesity of about 25% that was within the above-mentioned range for T1D, with no relationship with self-reported color-race and economic status, unlike in the USA, where the prevalence of overweight/obesity was higher among minorities [
39]. In multivariate analysis only gender, age, sBP persisted associated with overweight/obesity possibly due to our sample size that was smaller than those evaluated in other studies [
13,
37,
38]. Gender, age and sBP have been described as being associated with overweight/obesity in many different studies [
13,
14,
39].
A higher prevalence of MS was noted in patients with overweight/obesity in comparison to patients without this clinical condition. It is noteworthy that these latter patients still have a higher prevalence of MS than adolescents without T1D in Brazil which was 1.6% when the IDF criteria were used [
41]. A relationship between micro and macrovascular complications in patients with T1D with MS and each of its components has been observed [
4,
42]. In our study, hypertension, high sBP and dBP were some of the most important components of MS observed in patients with T1D and overweight/obesity similar to other studies, in T1D [
36] and in individuals without T1D [
41]. Nevertheless, no association between overweight/obesity with diabetic CKD and retinopathy was observed in the present study. The presence of hypertension, high sBP in the life-course of these patients is a risk factor for the development of these microvascular complications as has been previously demonstrated [
43,
44]. Another factor that could also be a background risk factor for the above-mentioned conditions was the family history of hypertension that was higher in the group of patients with overweight/obesity. No difference in the average value of HDL-cholesterol and triglycerides was found in our patients which was not observed in other studies [
36,
37]. This could be related to our sample size as well as to demographic characteristics of our population such as lower age and diabetes duration. Similar to other studies performed in patients with T1D, our patients showed a positive correlation between HbA1c and total cholesterol [
43]. Patients with overweight/obesity presented higher levels of total and LDL-cholesterol, which result in a higher risk for CVD [
37,
45]. We did not measure obesity-related hormones such as ghrelin which could have added some information regarding the pathogenesis of overweight/obesity in this group of patients. However, the role of this hormone in patients with T1D T1D is still controversial [
46].
Our data did not show an association between overweight/obesity with the levels of HbA1c, and with the number of patients that reached the targets for good glycemic control. Controversial results have been described in patients with T1D with overweight/obesity concerning glycemic control [
7,
12‐
14,
37]. A Dutch study showed average higher HbA1c levels in patients with overweight/obesity but without difference in the number of patients that presented HbA1c levels < 7.5% [
36]. The Finn Dianne study, that included adult patients with MS, showed its association with an inadequate glycemic control [
7].
Some studies showed an association between good glycemic control and overweight/obesity probably related to insulin intensive treatment [
11,
12]. This fact was not observed in our study. Although the majority of our patients were under the use of multiple insulin injections, less than 50% reported adherence to diet, and also less than 20% reported adherence to IRTs which has an impact upon glycemic control [
14,
17]. However, studies that have focused on the levels of HbA1c in patients with T1D, with and without overweight/obesity, have found a difference in HbA1c levels no greater than 0.5%.
An interesting point observed in the present study was the use of lower insulin doses (U/ kg/day) but higher total insulin dose (U/day) in patients with overweight/obesity. This probably occurred because these patients had higher body surface which could be related to insulin resistance that is usually found among these patients [
3,
4]. However, it is important to emphasize that the majority of the studies present their data taking in account insulin dosage as U/Kg/day, and the results regarding the presence of overweight/obesity is still controversial [
4,
33]
Finally, the use of metformin had a negative effect on overweight/obesity. It was used as adjunct therapy to insulin by 26.3% of our patients with overweight/obesity, mainly females (data not shown). Although these patients had similar levels of HbA1c, they used lower insulin doses than those with normal weight. Other studies that have also evaluated metformin in overweight/obese patients with T1D showed that metformin use was associated with significant reductions in HbA1c levels and insulin doses, with no significant changes in weight [
47]. Another study, conducted in Denmark, using metformin or placebo as adjunct to insulin did not find a significant difference on HbA1c levels, but the insulin doses and weight showed significant reductions [
48]. As expected, patients with overweight/obesity were more frequently using anti-hypertensive drugs and statins.
Our data were obtained and evaluated very uniformly and had a broad spectrum, which led us to evaluate many covariates, which was, consequently, a strength of our study.
Some limitations of our study must also be mentioned. Firstly, similar to other epidemiologic studies conducted with T1D [
13,
33], we did not measure C peptide levels, nor autoantibodies against beta cells, and used only clinical criteria for T1D diagnosis. Secondly, all the information about adherence to diet and to ITRs as well as practice of regular physical activity were self-reported. Thirdly, as we did not have the weight of the patients at the moment the diagnosis was made, we could not know if the presence of overweight/obesity was already present since then. Finally, as our study had a cross-sectional design, a causal relationship between those factors found to be associated with overweight/obesity and the presence of this clinical condition cannot be established.
Acknowledgements
We thank Mrs. Elisangela Santos, Maria Fátima Bevilacqua, Eliete Leão and Vitor Alves Branco, from the State University of Rio de Janeiro, for their technical assistance.
We also acknowledge the participants of Brazilian Type 1 Diabetes Study Group as follows:
Executive steering committee: Marilia Brito Gomes (chair), Carlos Antonio Negrato.
Principal investigators of each center are indicated by an asterisk.
Department of Internal Medicine, Diabetes Unit, State University of Rio de Janeiro, Brazil: Marilia Brito Gomes* (mariliabgomes@gmail.com).
Department of Internal Medicine, Diabetes Unit, State University of Rio de Janeiro, Brazil: Roberta Cobas (robertacobas@gmail.com) Lucianne Righeti Monteiro Tannus (luciannetannus@ig.com.br).
Federal University Hospital of Rio de Janeiro: Melanie Rodacki*, M.D. (mrodacki2001@yahoo.com.br); Lenita Zajdenverg, M.D. (lenitazaj@gmail.com) Joana Rodrigues Dantas, M.D. (joanardantasp@ig.com.br).
Diabetes Unit, University Hospital of São Paulo, São Paulo: Maria Lúcia Cardillo Corrêa-Giannella*, M.D. (malugia@lim25fm.usp.br); Sharon Nina Admoni, M.D. (sharonadmoni@ gmail.com); Daniele Pereira dos Santos, M.D. (dps.daniele@ hotmail.com).
Bauru’s Diabetics Association, Bauru, São Paulo: Carlos Antonio Negrato*, M.D. (carlosnegrato@uol.com.br); Maria de Fatima Guedes, M.D. (tatiguedeses@hotmail.com).
Diabetes Unit, Federal University of São Paulo State, São Paulo: Sergio Atala Dib*, M.D. (sergio.dib@unifesp.br); Celso Ferreira de Camargo Sallum Filho, M.D. (celsosallum@superig.com.br).
Diabetes Unit, University of Campinas, São Paulo: Elisabeth João Pavin*, M.D. (ejpavin@fcm.unicamp.br); Caroline Takano, M.D. (caroline.takano@gmail.com).
Clinical Hospital of the Federal University of Paraná: Rosângela Roginski Rea*, M.D. (rosangelarea@uol.com.br); Nicole Balster Romanzini, M.D. (nikbr@hotmail.com).
Clinical Hospital of Porto Alegre, Rio Grande do Sul: Mirela Azevedo*, M.D. (mirelajobimazevedo@gmail.com); Luis Henrique Canani, M.D. (luishenriquecanani@gmail.com).
Regional Hospital of Taguatinga, Brasília: Hermelinda Cordeiro Pedrosa*, M.D. (pedrosa.hc@globo.com); Monica Tolentino (monicatolentino@uol.com.br); Cejana Hamu Aguiar, M.D.
Diabetes and Endocrinology Center of Bahia: Reine Marie Chaves Fonseca*, M.D. (reinemar@terra.com.br); Ludmila Chaves Fonseca M.D., Raffaele Kasprowicz, M.D. (raffaellebarros@hotmail.com).
Diabetes and Hypertension Center of Ceará : Adriana Costa e Forti*, M.D. (adrianaforti@uol.com.br); Angela Delmira Nunes Mendes, M.D. (angeladelmira@terra.com.br).
Federal University of Ceará: Renan Montenegro Junior*, M. D. (renanjr@ufc.br); Virgínia Oliveira Fernandes, M.D. (virginiafernande@hotmail.com).
Federal University Hospital of Pará: João Soares Felício*, M. D. (felicio.bel@terra.com.br); Flavia Marques Santos, M.D. (drafms@bol.com.br).
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.